(Albany, USA) DelveInsight’s, “T-Cell Lymphoma Pipeline Insight, 2023” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about T-Cell Lymphoma pipeline report, click here @ T-Cell Lymphoma Drugs in different phases

 

Some facts of the T-Cell Lymphoma Pipeline report are:

• DelveInsight Evaluates a Robust T-Cell Lymphoma Pipeline as 120+ Influential Pharma Players to Set Foot in the Domain
• Leading T-Cell Lymphoma companies working in the market are Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma, Celgene, Celleron Therapeutics, Seagen, Nanjing Sanhome Pharmaceutical, Merck Sharp & Dohme, Medevir, Bristol Myers Squibb, Pfizer, Innate Pharma, Dizal Pharmaceutical, Hoffman-La-Roche, Affirmed, ImmuneOncia Therapeutics, CerRx, Shandong New Time Pharmaceutical, Secura Bio, Janssen Biotech, CStone Pharmaceutical, Galderma, Bioniz, Portola Pharmaceuticals, VidacPharma, Celgene Corporation, Shanghai Yingli Pharmaceutical, ViGenCell, Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, BeiGene, Kura Oncology, Rafael Pharmaceuticals, Eutilex, Yake Biotechnology, Rhizen Pharmaceuticals, Eli Lilly and Company, Onyx Pharmaceuticals, Astex Therapeutics, Aileron Therapeutics, Autolus, Akeso Biopharma, AVM Biotechnology, Ayala Pharmaceuticals, Trillium Therapeutics and others.
• Some of the T-Cell Lymphoma Drugs are SP-02, CC-486, IMC-001, Geptanolimab, Daratumumab, and others.

 

Request for a sample to know more about the T-Cell Lymphoma clinical trial advancements @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight

 

T-Cell Lymphoma Overview:

T cell lymphomas (TCL) are a very heterogeneous group of lymphoid malignancies derived from mature T cells differing by localization, pathological features, and clinical presentation. T-Cell Lymphomas can develop in lymphoid tissues such as the lymph nodes and spleen or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). 

 

T-Cell Lymphoma Emerging Drugs

SP-02: Solasia Pharma

SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, darinaparsin demonstrated clinical activity evidence in lymphoma, particularly PTCL. Furthermore, the Phase I study done in the US and the Pan-Asian Phase 1 study demonstrated positive efficacy and safety of SP-02. The drug is currently being evaluated in Phase III clinical trials to treat patients with Peripheral T Cell Lymphoma. Solasia has begun preparing for the NDA Filing of SP-02.

CC-486: Celgene

CC-486 (Azacitidine) is an orally-active form of Vidaza, a chemical analog of the cytosine nucleoside used in DNA and RNA. The main mechanism of action is thought to be hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. CC-486 is indicated for the treatment of acute myeloid leukemia in first remission. The drug is in Phase III clinical studies for the treatment of T-Cell Lymphoma.

 

Request for a sample to get detailed analysis of T-Cell Lymphoma therapies, click here@ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight

 

T-Cell Lymphoma Pipeline Therapeutic Assessment

There are approx. 85+ key companies which are developing the therapies for T-Cell Lymphoma. The companies which have their T-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Solasia Pharma and others.

 

Scope of the T-Cell Lymphoma Pipeline Report

• Coverage- Global
• T-Cell Lymphoma Pipeline Assessment: Product Type, Molecule Type, Mechanism of Action, Route of Administration

• T-Cell Lymphoma Companies– Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma, Celgene, Celleron Therapeutics, Seagen, Nanjing Sanhome Pharmaceutical, Merck Sharp & Dohme, Medevir, Bristol Myers Squibb, Pfizer, Innate Pharma, Dizal Pharmaceutical, Hoffman-La-Roche, Affirmed, ImmuneOncia Therapeutics, CerRx, Shandong New Time Pharmaceutical, Secura Bio, Janssen Biotech, CStone Pharmaceutical, Galderma, Bioniz, Portola Pharmaceuticals, VidacPharma, Celgene Corporation, Shanghai Yingli Pharmaceutical, ViGenCell, Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, BeiGene, Kura Oncology, Rafael Pharmaceuticals, Eutilex, Yake Biotechnology, Rhizen Pharmaceuticals, Eli Lilly and Company, Onyx Pharmaceuticals, Astex Therapeutics, Aileron Therapeutics, Autolus, Akeso Biopharma, AVM Biotechnology, Ayala Pharmaceuticals, Trillium Therapeutics and others.

• T-Cell Lymphoma Pipeline Therapies- SP-02, CC-486, IMC-001, Geptanolimab, Daratumumab, and others.

 

Learn more about the emerging T-Cell Lymphoma pipeline therapies @ T-Cell Lymphoma Clinical Trials Analysis – https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight

 

Table of Content

Introduction

Executive Summary

T-Cell Lymphoma: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

T-Cell Lymphoma Pipeline Therapeutics

• Comparative Analysis

T-Cell Lymphoma Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Late Stage Products (Pre-registration)

• Comparative Analysis

Geptanolimab: Genor Biopharma

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Late Stage Products (Phase III)

• Comparative Analysis

SP-02: Solasia Pharma

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

IMC-001: ImmuneOncia Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

• Comparative Analysis

Tolinapant: Astex Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

T-Cell Lymphoma Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

TTI-621: Trillium Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

• Comparative Analysis

BBI 3000: Brickell Biotech Inc

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

T-Cell Lymphoma Key Companies

T-Cell Lymphoma Key Products

T-Cell Lymphoma- Unmet Needs

T-Cell Lymphoma Market Drivers and Barriers

T-Cell Lymphoma Future Perspectives and Conclusion

T-Cell Lymphoma Analyst Views

T-Cell Lymphoma Key Companies

Appendix

 

Request for free sample @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services